Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|August 31, 2011
Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoterAhmed M Albarrag, Michael J Anderson, Susan J Howard, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2010
Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosisJodi M Lestner, Susan J Howard, Joanne Goodwin, et al.
The Journal of Infectious Diseases|March 2, 2011
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapySusan J Howard, Jodi M Lestner, Andrew Sharp, et al.
Antimicrobial Agents and Chemotherapy|August 3, 2011
Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsSusan J Howard, Joanne Livermore, Andrew Sharp, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2012
Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administrationZaid Al-Nakeeb, Ajay Sudan, Adam R Jeans, et al.
Emerging Infectious Diseases|July 24, 2009
Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failureSusan J Howard, Dasa Cerar, Michael J Anderson, et al.
The Journal of Infectious Diseases|May 29, 2012
Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpointsAdam R Jeans, Susan J Howard, Zaid Al-Nakeeb, et al.
Antimicrobial Agents and Chemotherapy|April 11, 2013
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpointsAjay Sudan, Joanne Livermore, Susan J Howard, et al.
Mbio|January 30, 2014
Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 daysJoanne Livermore, Susan J Howard, Andrew D Sharp, et al.
The Journal of Infectious Diseases|April 20, 2013
Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patientsLucy O'Connor, Joanne Livermore, Andrew D Sharp, et al.
Pageof 4